LovastatinThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7

326 records returned

Lovastatin-induced cholesterol depletion affects both apical sorting and endocytosis of aquaporin-2 in renal cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vasopressin causes the redistribution of the water channel aquaporin-2 (AQP2) from cytoplasmic storage vesicles to the apical plasma membrane of collecting duct principal cells, leading to urine concentration. The molecular mechanisms regulating the selective apical sorting of AQP2 are only partially uncovered. In this work, we investigate whether AQP2 sorting/trafficking is regulated by its association with membrane rafts. In both MCD4 cells and rat kidney, AQP2 preferentially associated with Lubrol WX-insoluble membranes regardless of its presence in the storage compartment or at the apical membrane. Block-and-release ex...
Source: AJP: Renal Physiology - January 27, 2010 Category: Urology & Nephrology Authors: Procino, G., Barbieri, C., Carmosino, M., Rizzo, F., Valenti, G., Svelto, M. Tags: ARTICLES Source Type: journals

Lovastatin in X-Linked AdrenoleukodystrophyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To the Editor: As reported previously in the Journal, lovastatin lowers levels of very-long-chain fatty acids in plasma in patients ... (Source: New England Journal of Medicine)
Source: New England Journal of Medicine - January 20, 2010 Category: Internal Medicine Authors: Engelen, M., Ofman, R., Dijkgraaf, M. G.W., Hijzen, M., van der Wardt, L. A., van Geel, B. M., de Visser, M., Wanders, R. J.A., Poll-The, B. T., Kemp, S. Tags: CORRESPONDENCE Source Type: journals

Hormone and pharmaceutical regulation of ASP production in 3T3-L1 adipocytesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several studies have demonstrated increases in acylation stimulating protein (ASP), and precursor protein C3 in obesity, diabetes and dyslipidemia, however the nature of the regulation is unknown. To evaluate chronic hormonal and pharmaceutical mediated changes in ASP and potential mechanisms, 3T3-L1 adipocytes were treated with physiological concentrations of relevant hormones and drugs currently used in treatment of metabolic diseases for 48 h. Medium ASP production and C3 secretion were evaluated in relation to changes in adipocyte lipid metabolism (cellular triglyceride (TG) mass, non-esterified fatty acid (NEFA) relea...
Source: Journal of Cellular Biochemistry - January 12, 2010 Category: Biochemistry Authors: Ying Gao, Danny Gauvreau, Katherine Cianflone Source Type: journals

Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nanostructured lipid carriers (NLCs) made from mixtures of Precirol and squalene were prepared to investigate whether the bioavailability of lovastatin can be improved by oral delivery. The size, zeta potential, drug loading capacity, and release properties of the NLCs were compared with those of lipid nanoparticles containing pure Precirol (solid lipid nanoparticles, SLNs) and squalene (lipid emulsions, LEs). Stable nanoparticles with a mean size range of 180 approximately 290 nm and zeta potential range of -3 to -35 mV were developed. More than 70% lovastatin was entrapped in the NLCs and LEs, which was significantly...
Source: European Journal of Pharmaceutics and Biopharmaceutics - January 6, 2010 Category: Drugs & Pharmacology Authors: Chen CC, Tsai TH, Huang ZR, Fang JY Tags: Eur J Pharm Biopharm Source Type: journals

Ethanol Enhances Hepatitis C Virus Replication through Lipid Metabolism and Elevated NADH/NAD+ [Metabolism and Bioenergetics]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Therefore, lipid metabolism and alteration of cellular NADH/NAD+ ratio are likely to play a critical role in the potentiation of HCV replication by ethanol rather than oxidative stress. (Source: Journal of Biological Chemistry)
Source: Journal of Biological Chemistry - January 1, 2010 Category: Chemistry Authors: Seronello, S., Ito, C., Wakita, T., Choi, J. Tags: Metabolism and Bioenergetics Source Type: journals

LOVASTATIN (Lovastatin) Tablet [Mutual Pharmaceutical Company, Inc.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Dec 22, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - December 22, 2009 Category: Drugs & Pharmacology Source Type: organizations

HMG-CoA reductase inhibitor lovastatin upregulates plasminogen activator production through RhoA-signaling in peritoneal cell line Met5AEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was conducted to determine if hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor statin, known to protect postoperative adhesion in animal model, affect the expressing tissue-type plasminogen activator (tPA) in peritoneal cells in culture. Human peritoneal Met5A cells were used to examine the effects of hydrophobic statin lovastatin on the level of tPA. PA concentrations were measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Active RhoA form was also examined. Lovastatin caused concentration-dependent tPA expression associated with fall of RhoA active level in Met5A...
Source: Gynecological Surgery - December 21, 2009 Category: OBGYN Tags: Gynecological Surgery Source Type: journals

Kaletra tablets and liquid (ritonavir/lopinavir) - Revised SPCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Revised SPC includes changes to: Section 4.3 - Contraindications - contraindication for use of lovastatin, simvastatin, sildenafil used for treatment of pulmonary arterial hypertension and vardenafil. Section 4.4 - Special warnings and precautions for Use - change to caution statement regarding PDE5 inhibitors. Section 4.5 - Interaction with other medicinal products and other forms of interaction - updated the information concerning the interaction of ritonavir, with tipranavir Section 5.1 - Pharmacodynamic Properties - ...
Source: NeLM - SPC Changes - December 21, 2009 Category: Drugs & Pharmacology Source Type: organizations

Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Lovastatin increased the absorption of verapamil by inhibiting P-gp and inhibited the first-pass metabolism of verapamil by inhibiting CYP3A4 in the intestine and/or liver in humans. Content Type Journal ArticleCategory Pharmacokinetics and DispositionDOI 10.1007/s00228-009-0757-xAuthors Dong-Hyun Choi, Chosun University College of Medicine Dong-Gu, Gwangju 501-759 Republic of KoreaJoong-Hwa Chung, Chosun University College of Medicine Dong-Gu, Gwangju 501-759 Republic of KoreaJun-Shik Choi, Chosun University BK21 Team, College of Pharmacy 375, Su-suk Dong Dong-Gu, Gwangju 501-759 Republic o...
Source: European Journal of Clinical Pharmacology - December 12, 2009 Category: Drugs & Pharmacology Tags: European Journal of Clinical Pharmacology Source Type: journals

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Disease Focused Reviews CRD Summary: This generally well-conducted review concluded that statin use in patients without established cardiovascular disease, but with cardiovascular risk factors, was associated with significantly improved survival and large reductions in the risk of major cardiovascular events. This conclusion reflected the results of an appropriate synthesis of large, high-quality trials and is likely to be reliable. [Included studies used pravastatin, lovastatin, atorvastatin, simvastatin or rosuvastatin.] CRD Commentary: The review question was clear and supported by spe...
Source: NeLM - Cerebrovascular Disorders - December 11, 2009 Category: Neurology Source Type: organizations

Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Alpha-synuclein (alpha-syn) aggregation is a neuropathological hallmark of many diseases including Dementia with Lewy Bodies (DLB) and Parkinson's Disease (PD), collectively termed the alpha-synucleinopathies. The mechanisms underlying alpha-syn aggregation remain elusive though emerging science has hypothesized that the interaction between cholesterol and alpha-syn may play a role. Cholesterol has been linked to alpha-synucleinopathies by recent work suggesting cholesterol metabolites appear to accelerate alpha-syn fibrilization. Consistent with these findings, cholesterol-lowering agents have been demonstrated to red...
Source: Experimental Neurology - November 24, 2009 Category: Neurology Authors: Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E Tags: Exp Neurol Source Type: journals

Effect of Lovastatin on Primary Prevention of Cardiovascular Events in Mild CKD and Kidney Function Loss: A Post Hoc Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention StudyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Lovastatin is effective for the primary prevention of CVD in patients with CKD, but is not effective in decreasing kidney function loss in persons with no CVD. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - November 23, 2009 Category: Urology & Nephrology Authors: Jessica Kendrick, Michael G. Shlipak, Giovanni Targher, Thomas Cook, Joann Lindenfeld, Michel Chonchol Tags: Pathogenesis and Treatment of Kidney Disease Source Type: journals

Lovastatin-induced cholesterol depletion affects both apical sorting and endocytosis of aquaporin 2 in renal cells.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
LOVASTATIN-INDUCED CHOLESTEROL DEPLETION AFFECTS BOTH APICAL SORTING AND ENDOCYTOSIS OF AQUAPORIN 2 IN RENAL CELLS. Am J Physiol Renal Physiol. 2009 Nov 18; Authors: Procino G, Barbieri C, Carmosino M, Rizzo F, Valenti G, Svelto M Vasopressin causes the redistribution of the water channel aquaporin 2 (AQP2) from cytoplasmic storage vesicles to the apical plasma membrane of collecting duct principal cells leading to urine concentration. The molecular mechanisms regulating the selective apical sorting of AQP2 are only partially uncovered. In this work we investigate whether AQP2 sorting/trafficking is regulated b...
Source: American Journal of Physiology. Renal Physiology - November 18, 2009 Category: Physiology Authors: Procino G, Barbieri C, Carmosino M, Rizzo F, Valenti G, Svelto M Tags: Am J Physiol Renal Physiol Source Type: journals

Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug LovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers have for the first time, successfully reconstituted one of the most interesting but least understood enzymes in the highly reducing iterative polyketide synthases found in filamentous fungi. This enzyme is responsible for producing the cholesterol-lowering compound lovastatin. Lovastatin is a blockbuster drug used for lowering cholesterol in those with hypercholesterolemia, and thus helps to prevent cardiovascular disease. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 10, 2009 Category: Science Source Type: news

UCLA Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug LovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. The research, published Oct. 23 in the journal Science, could potentially lead to the development of other compounds with similarly beneficial effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 5, 2009 Category: Consumer Health News Tags: Statins Source Type: news

UCLA Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug LovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. The research, published Oct. 23 in the journal Science, could potentially lead to the development of other compounds with similarly beneficial effects. (Source: Cholesterol News From Medical News Today)
Source: Cholesterol News From Medical News Today - November 5, 2009 Category: Cardiology Tags: Statins Source Type: news

UCLA Researchers Reconstitute Enzyme That Synthesizes Cholesterol Drug LovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. The research, published Oct. 23 in the journal Science, could potentially lead to the development of other compounds with similarly beneficial effects... (Source: Cholesterol News From Medical News Today)
Source: Cholesterol News From Medical News Today - November 5, 2009 Category: Cardiology Tags: Statins Source Type: news

Finding May Expedite Cholesterol Drug ProductionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers funded by NIGMS have successfully reconstituted the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. (Source: NIGMS - Results)
Source: NIGMS - Results - November 4, 2009 Category: Biomedical Science Source Type: news

UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(University of California - Los Angeles) Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time, successfully reconstituted one of the most interesting but least understood enzymes in the highly reducing iterative polyketide synthases found in filamentous fungi. This enzyme is responsible for producing the cholesterol-lowering compound lovastatin. Lovastatin is a blockbuster drug used for lowering cholesterol in those with hypercholesterolemia, and thus helps to prevent cardiovascular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2009 Category: Global & Universal Source Type: news

Directed evolution and structural characterization of a simvastatin synthase.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Enzymes from natural product biosynthetic pathways are attractive candidates for creating tailored biocatalysts to produce semisynthetic pharmaceutical compounds. LovD is an acyltransferase that converts the inactive monacolin J acid (MJA) into the cholesterol-lowering lovastatin. LovD can also synthesize the blockbuster drug simvastatin using MJA and a synthetic alpha-dimethylbutyryl thioester, albeit with suboptimal properties as a biocatalyst. Here we used directed evolution to improve the properties of LovD toward semisynthesis of simvastatin. Mutants with improved catalytic efficiency, solubility, and thermal stab...
Source: Chemistry & Biology - October 30, 2009 Category: Chemistry Authors: Gao X, Xie X, Pashkov I, Sawaya MR, Laidman J, Zhang W, Cacho R, Yeates TO, Tang Y Tags: Chem Biol Source Type: journals

In vitro interactions between primycin and different statins in their effects against some clinically important fungi.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The in vitro antifungal activities of primycin and various statins against some opportunistic pathogenic fungi were investigated. Primycin completely inhibited the growth of Candida albicans (MIC: 64 microg ml(-1)) and Candida glabrata (MIC: 32 microg ml(-1)), and was very effective against Paecilomyces variotii (MIC: 2 microg ml(-1)), but it had little effect on Aspergillus fumigatus, Aspergillus flavus or Rhizopus oryzae (MIC: >64 microg ml(-1)). The fungi exhibited different degrees of sensitivity to the statins; fluvastatin and simvastatin exerted potent antifungal activities against a wide variety of clinically...
Source: Journal of Medical Microbiology - October 29, 2009 Category: Microbiology Authors: Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C Tags: J Med Microbiol Source Type: journals

Bundling Two Low-cost Heart Drugs Prevents Heart Attack And Stroke In Large, Diverse PopulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study found that bundling two generic, low-cost drugs -- a cholesterol-lowering statin and a blood pressure-lowering drug -- and giving daily doses to 68,560 people with diabetes or heart disease for two years prevented 1,271 heart attacks and strokes. The clinical observational study followed 170,024 ethnically diverse Californians and found that offering lovastatin and lisinopril daily for two years reduced risk of hospitalization for heart attack or stroke by more than 60 percent. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - October 28, 2009 Category: Science Source Type: news

Beware of swine flu internet scams, counterfeit medicinesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NaturalNews) With the swine flu pandemic upon us, the FDA is warning people to beware of swine flu scams on the internet. NaturalNews is joining in the warnings today, urging people to beware of scams that cost big money but simply don't work to prevent H1N1 swine flu.For example, both the FDA and CDC are pushing a collection of swine flu vaccines that have never been subjected to any scientific testing to determine whether they actually work. These vaccines are, in technical terms, a "hoax." Lacking any scientific evidence of efficacy, they are a scam that should be avoided by all health consumers.You can learn more abou...
Source: NaturalNews.com - October 24, 2009 Category: Consumer Health Advice Source Type: news

Dissecting Megaenzyme MechanismsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Filamentous fungi contain a class of multidomain enzymes, the highly-reducing iterative polyketide synthases (HR-IPKSs), which produce important natural products such as the cholesterol-lowering drug lovastatin. To produce their complex products, … [Read more] (Source: This Week in Science)
Source: This Week in Science - October 23, 2009 Category: Science Authors: Stewart Wills (mailto:swills at aaas.org) Source Type: journals

Biotechnological production and applications of statins.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Statins are a group of extremely successful drugs that lower cholesterol levels in blood; decreasing the risk of heath attack or stroke. In recent years, statins have also been reported to have other biological activities and numerous potential therapeutic uses. Natural statins are lovastatin and compactin, while pravastatin is derived from the latter by biotransformation. Simvastatin, the second leading statin in the market, is a lovastatin semisynthetic derivative. Lovastatin is mainly produced by Aspergillus terreus strains, and compactin by Penicillium citrinum. Lovastatin and compactin are produced industrially by...
Source: Applied Microbiology and Biotechnology - October 9, 2009 Category: Microbiology Authors: Barrios-González J, Miranda RU Tags: Appl Microbiol Biotechnol Source Type: journals

Decreasing risk of death by 80% at the cost of $12 per monthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
High-risk patients who took 3 older drugs - statin, lisinopril, aspirin - cut risk of a heart attack or stroke by 80% (source: Reuters).All of those are on the Walmart's $4 list which means you can decrease your risk of death by 80% for $12 per month (if you have the risk factors)."Even in people who took it less than half the time, they got over a 60 percent drop in heart attacks and strokes," said Dr. R. James Dudl of Kaiser Permanente in California, whose study was published in the American Journal of Managed Care. "Those who took it more than half the time -- they got more like an 80 percent drop."It also suggests that...
Source: Clinical Cases and Images - October 4, 2009 Category: Journals (General) Tags: Medications Cardiology Source Type: info

Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Progression of colon cancer is associated with the up-regulation of cyclooxygenase-2 (COX-2) and hydroxymethyl glutaryl CoA reductase (HMG-R). Clinical and preclinical evidence shows that a combination of COX-2 and HMG-R inhibitors provide additive/synergistic chemopreventive effects against colorectal cancer. However, the mechanism by which statins and NSAIDs inhibit cancer growth is not yet fully understood. We aimed to identify critical molecules and signal pathways modulated by a combination of lovastatin and celecoxib in the human HCT-116 colon cancer cell line. HCT-116 cells were exposed to 50 microM celecoxib, 2...
Source: International Journal of Oncology - October 1, 2009 Category: Cancer & Oncology Authors: Guruswamy S, Rao CV Tags: Int J Oncol Source Type: journals

Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pilot-scale libraries of eight-membered medium ring lactams (MRLs) and related tricyclic compounds (either seven-membered lactams, thiolactams or amines) were screened for their ability to inhibit the catalytic activity of human recombinant 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in vitro. A dozen of the synthetic compounds mimic the inhibition of purified HMG-CoA reductase activity caused by pravastatin, fluvastatin and sodium salts of lovastatin, mevastatin and simvastatin in this cell-free assay, suggesting direct interaction with the rate-limiting enzyme of cholesterol biosynthesis. Moreover, seve...
Source: International Journal of Molecular Medicine - October 1, 2009 Category: Molecular Biology Authors: Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, Lushington GH Tags: Int J Mol Med Source Type: journals

Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: Possible role of P-glycoprotein inhibition by lovastatin.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was to investigate the effect of lovastatin on the bioavailability or pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats. The pharmacokinetic parameters of verapamil and norverapamil in rats were measured after the oral administration of verapamil (9 mg/kg) in the presence or absence of lovastatin (0.3 or 1.0 mg/kg). The pharmacokinetic parameters of verapamil were significantly altered by the presence of lovastatin compared to the control group (given verapamil alone). The presence of lovastatin significantly (p < 0.05, 0.3 mg/kg; p < 0.01, 1.0 mg/kg) increased the total area un...
Source: Archives of Pharmacal Research - October 1, 2009 Category: Drugs & Pharmacology Authors: Hong SP, Chang KS, Koh YY, Choi DH, Choi JS Tags: Arch Pharm Res Source Type: journals

Bundling 2 Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse PopulationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
October 1, 2009 (EurekAlert) - A program that bundled two generic, low-cost drugs – a cholesterol-lowering statin and a blood pressure-lowering drug – and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care. Kaiser Permanente developed the ALL initiative (Aspirin, Lisinopril and Lipid-Lowering Medication) in 2003 to reduce heart attacks and strokes by aggressively enrolling patients wit...
Source: Diabetes News from dLife.com - September 30, 2009 Category: Consumer Health News Authors: dlife Source Type: info

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we investigated the effect of combining lovastatin with gefitinib on gefitinib-resistant human non-small cell lung cancer (NSCLC) cell lines with K-Ras mutations. Antitumor effects were measured by growth inhibition and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Effects on apoptosis were determined by flow cytometry, DNA fragmentation, and immunoblots. Protein levels of RAS, AKT/pAKT, and RAF/ERK1/2 in cancer cells were analyzed by immunoblot. Compared with gefitinib alone, a combination of gefitinib with lovastatin showed significantly enhanced cell growth inhibition and cytoto...
Source: Investigational New Drugs - September 17, 2009 Category: Drugs & Pharmacology Tags: Investigational New Drugs Source Type: journals

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow TransplantationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Graft-versus-host disease (GVHD) following bone marrow transplantation (BMT) is mediated by alloreactive donor T lymphocytes. Migration and activation of donor-derived T lymphocytes play critical roles in the development of GVHD. Leukocyte function–associated antigen-1 (LFA-1) regulates T cell adhesion and activation. We previously demonstrated that the I-domain, the ligand-binding site of LFA-1, changes from the low-affinity state to the high-affinity state on LFA-1 activation. Therapeutic antagonists, such as statins, inhibit LFA-1 activation and immune responses by modulating the affinity state of the LFA-1 I-domain. ...
Source: Biology of Blood and Marrow Transplantation - September 14, 2009 Category: Hematology Authors: Yang Wang, Dan Li, Dan Jones, Roland Bassett, George E. Sale, Jahan Khalili, Krishna V. Komanduri, Daniel R. Couriel, Richard E. Champlin, Jeffrey J. Molldrem, Qing Ma Tags: Biology Source Type: journals

Lovastatin Reduces Coronary Events Based on CholesterolEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patients with no cardiovascular risk factors who take lovastatin have a lower risk of developing major coronary events if they have substantial increases in high-density lipoprotein cholesterol and substantial decreases in low-density lipoprotein cholesterol in the first year of treatment, according to a study in the Sept. 15 issue of the American Journal of Cardiology. (Source: Modern Medicine)
Source: Modern Medicine - September 13, 2009 Category: Journals (General) Source Type: info

Greatest CVD risk reduction with low LDL and high HDL cholesterolEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
US researchers report that lovastatin therapy produces the greatest reduction in acute major coronary events for patients when low-density lipoprotein cholesterol is substantially reduced and high-density lipoprotein cholesterol is increased by at least 7.5%. (Source: MedWire News - Lipidology)
Source: MedWire News - Lipidology - September 11, 2009 Category: Lipidology Source Type: news

Effects of Increasing High-Density Lipoprotein Cholesterol and Decreasing Low-Density Lipoprotein Cholesterol on the Incidence of First Acute Coronary Events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, lovastatin therapy was associated with a greater risk reduction of AMCEs when LDL cholesterol was substantially reduced and the HDL cholesterol increased by ≥7.5%. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - September 7, 2009 Category: Cardiology Authors: Yadong Cui, Douglas J. Watson, Cynthia J. Girman, Deborah R. Shapiro, Antonio M. Gotto, Patricia Hiserote, Michael B. Clearfield Tags: Preventive Cardiology Source Type: journals

A Comparison of Pectin, Polyphenols, and Phytosterols, Alone or in Combination, to Lovastatin for Reduction of Serum Lipids in Familial Hypercholesterolemic SwineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Medicinal Food Aug 2009, Vol. 12, No. 4: 854-860. (Source: Journal of Medicinal Food)
Source: Journal of Medicinal Food - September 7, 2009 Category: Nutrition Tags: article Source Type: journals

The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitroEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, the current data suggest that ZOL-induced IPP/ApppI formation can contribute to ZOL-induced apoptosis. This mechanism and the inhibition of protein prenylation, both outcomes of FPPS inhibition in mevalonate pathway, seem to act in concert in ZOL-induced apoptosis in cancer cells. (Source: Bone)
Source: Bone - September 7, 2009 Category: Orthopaedics Authors: Laura M. Mitrofan, Jukka Pelkonen, Jukka Mönkkönen Tags: Original Articles Source Type: journals

FDA says link may exist between statin drugs and Lou Gehrig'sEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Q: My husband started on lovastatin for high cholesterol and soon began to notice weakness in his right arm. This weakness progressed, so he saw his doctor, thinking he had a pinched nerve. He was referred to a neurologist, who gave him a diagnosis of... (Source: OrlandoSentinel: Medical Research)
Source: OrlandoSentinel: Medical Research - September 4, 2009 Category: American Health Source Type: news

A simple and sensitive HPLC-UV method for quantitation of lovastatin in human plasma: Application to a bioequivalence study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An available, simple, sensitive, and rapid method has been developed for determination of the 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor, lovastatin in human plasma. The analytical procedure involves a one-step liquid-liquid extraction method using atorvastatin as internal standard. Chromatographic separation was carried out on a reversed phase C(18) column using a mixture of 0.05 M phosphate buffer (pH 7) and acetonitrile (44.5 : 55.5, v/v) as mobile phase with UV detection set at 238 nm. The total run time of analysis was 6 min with the retention time of lovastatin being 4.3 min. A complete set of analy...
Source: Biological and Pharmaceutical Bulletin - August 31, 2009 Category: Drugs & Pharmacology Authors: Hamidi M, Zarei N, Shahbazi MA Tags: Biol Pharm Bull Source Type: journals

Enhancement of Lovastatin Production by Supplementing Polyketide Antibiotics to the Submerged Culture of Aspergillus terreus.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Feedback inhibition existed in lovastatin biosynthesis from Aspergillus terreus. Exogenous lovastatin and other different polyketide antibiotics biosynthesized by polyketide synthase were supplemented to the cultures of A. terreus to investigate their influences on lovastatin production. Supplementing exogenous lovastatin of 100 mg l(-1) at the early stage of fermentation and the fast stage of its biosynthesis resulted in decreases of 76.4% and 20% in final lovastatin production, respectively. However, the fungal cell growth was not affected; the growing cycle was only prolonged in the submerged cultivation. Separate s...
Source: Applied Biochemistry and Biotechnology - August 29, 2009 Category: Biochemistry Authors: Jia Z, Zhang X, Zhao Y, Cao X Tags: Appl Biochem Biotechnol Source Type: journals

Gemfibrozil/linezolid/lovastatin interaction: Elevated CK levels associated with linezolid or lovastatin or a drug interaction, in an elderly patient: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - August 24, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Molecular mechanisms underlying the cholesterol-lowering effect of Ginkgo biloba extract in hepatocytes: a comparative study with lovastatin.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion:By using a gene expression profiling approach, we were able to broaden the understanding of the molecular mechanisms by which GBE lowers cellular cholesterol levels. Specifically, we demonstrated that GBE exhibited dual effects on the cellular cholesterol pool by modulating both HMG-CoA reductase activity and inhibiting cholesterol influx.Acta Pharmacologica Sinica advance online publication, 24 August 2009; doi: 10.1038/aps.2009.126. PMID: 19701231 [PubMed - as supplied by publisher] (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - August 23, 2009 Category: Drugs & Pharmacology Authors: Xie ZQ, Liang G, Zhang L, Wang Q, Qu Y, Gao Y, Lin LB, Ye S, Zhang J, Wang H, Zhao GP, Zhang QH Tags: Acta Pharmacol Sin Source Type: journals

Fluvastatin and lovastatin inhibit granulocyte macrophage–colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditionsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Eosinophil accumulation in the lung is an important feature of airway inflammation in asthma. There is therefore much interest in developing novel therapies to prevent this process. Accumulating evidence suggests that statins have anti-inflammatory properties, including inhibition of leucocyte accumulation. We therefore assessed the ability of five statins to inhibit human eosinophil adhesion to recombinant human inter-cellular adhesion molecule (rhICAM)-1 under physiologically relevant flow conditions. Purified eosinophils were pre-treated with a panel of statins before elucidation of the adhesion profiles of resting and ...
Source: Clinical and Experimental Allergy - August 17, 2009 Category: Allergy & Immunology Authors: A. J. Robinson, D. Kashanin, F. O'Dowd, K. Fitzgerald, V. Williams, G. M. Walsh Source Type: journals

A systematic review and meta-analysis on the therapeutic equivalence of statinsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study will use systematic review to compare the efficacy and safety profiles of different statins at different doses and determine the therapeutically equivalent doses of statins to achieve a specific level of low-density lipoprotein cholesterol (LDL-C) lowering effect.Methods: Publications of head-to-head randomized controlled trials (RCTs) of statins were retrieved from the Oregon state database (1966[ndash]2004), MEDLINE (2005-April of 2006), EMBASE (2005-April of 2006), and the Cochrane Controlled Trials Registry (up to the first quarter of 2006). The publications were evaluated with predetermined criteria by a re...
Source: Journal of Clinical Pharmacy and Therapeutics - August 13, 2009 Category: Drugs & Pharmacology Authors: T.-C. Weng, Y.-H. Kao Yang, S.-J. Lin, S.-H. Tai Source Type: journals

Inhibition of Platelet-Rich Arterial Thrombus In Vivo. Acute Antithrombotic Effect of Intravenous HMG-CoA Reductase Therapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Sequential arterial injury augments the thrombotic response suggesting that the propensity for arterial thrombosis is at least partially acquired. This thrombotic augmentation can be acutely attenuated by intravenous lovastatin which may result from a pleiotropic impact on platelet function. These results appear to be a class effect of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors. PMID: 19667107 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - August 9, 2009 Category: Cardiology Authors: Obi C, Wysokinski W, Karnicki K, Owen WG, McBane RD Tags: Arterioscler Thromb Vasc Biol Source Type: journals

The isoprenoid pathway and transcriptional response to its inhibitors in the yeast Saccharomyces cerevisiaeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This review presents new insights into the regulation of the isoprenoid pathway in the yeast Saccharomyces cerevisiae, in particular the short-term transcriptional response to two inhibitors, lovastatin and zaragozic acid (ZA). Whereas lovastatin blocks whole isoprenoid pathway, ZA only blocks the sterol branch. Consequently, their effects on the cellular level of farnesyl diphosphate (FPP) are different. Lovastatin decreases the FPP level, whereas ZA, by inhibiting the main FPP-consuming enzyme, increases FPP availability in the cell. We discuss the role of genes whose expression is affected by both inhibitors and conside...
Source: FEMS Yeast Research - August 4, 2009 Category: Research Authors: Klaudia Kuranda, Jean François, Grażyna Palamarczyk Source Type: journals

Cloning and bioinformatic analysis of lovastatin biosynthesis regulatory gene lovE.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: In the lovastatin biosynthesis process lovE is a regulatory gene and LovE protein is a GAL4-like transcriptional factor. PMID: 19781329 [PubMed - in process] (Source: Chinese Medical Journal)
Source: Chinese Medical Journal - August 4, 2009 Category: Journals (General) Authors: Huang X, Li HM Tags: Chin Med J (Engl) Source Type: journals

Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitroEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, an impairment of the protein prenylation, especially geranylgeranylation, resulted predominantly in the potentiation of the cytostatic/cytotoxic activity of sorafenib, in cell cycle arrest in G1 phase, and, in poor induction of apoptosis. Moreover, due to the fact that it has been well documented that sorafenib compromises the heart function, we studied the interaction of lovastatin and sorafenib using rat cardiomyoblast line H9c2. The combination showed strong synergistic cardiotoxic effects. Statins and tyrosine kinase inhibitors were used at doses that are achievable clinically, which makes the combinatio...
Source: Cancer Letters - July 27, 2009 Category: Cancer & Oncology Authors: Jacek Bil, Lukasz Zapala, Dominika Nowis, Marek Jakobisiak, Jakub Golab Tags: Regular Articles Source Type: journals

Effect of Folate Supplementation on Serum Homocysteine and Plasma Total Antioxidant Capacity in Hypercholesterolemic Adults under Lovastatin Treatment: A Double-blind Randomized Controlled Clinical TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study was performed to evaluate the effects of folate supplementation on lowering Hcy level and changes of TAC in asymptomatic hypercholesterolemic adults under lovastatin treatment.Methods: This was a double-blind randomized controlled clinical trial. Forty asymptomatic newly diagnosed hypercholesterolemic individuals were recruited. Patients were randomized into two groups: group A—20 patients supplemented for 8 weeks with folate (5mg daily) and group B—20 patients receiving placebo. Lovastatin was administered to both groups. Laboratory lipid profiles, serum Hcy and folate concentration, and TAC were measured a...
Source: Archives of Medical Research - July 26, 2009 Category: Research Authors: Farzad Shidfar, Reza Homayounfar, Seyed-Mohammad Fereshtehnejad, Alireza Kalani Tags: Clinical Source Type: journals

Simvastatin- and Fluvastatin-Associated NightmaresEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The authors present a case of nightmares induced by the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors simvastatin and fluvastatin. A 79-year-old Caucasian male initially treated with simvastatin 10 mg every evening developed nightmares after the dose was increased to 40 mg. No relief was provided with a dose reduction to 20 mg, and simvastatin was held. Simvastatin was restarted 7 weeks later at 10 mg, with no complaints of nightmares until the dose was escalated to 20 mg. Simvastatin therapy was subsequently stopped. One month later, fluvastatin 80 mg was initiated and nightmares returned within 3 mo...
Source: Journal of Pharmacy Practice - July 21, 2009 Category: Drugs & Pharmacology Authors: Wood, R. L., Cummins, D. F. Tags: Adverse Drug Reactions Source Type: journals